Jade Biosciences

Waltham, Massachusetts, United States · Biotechnology, Healthcare, Health Care · 50 employees

Jade Biosciences is a clinical-stage biotechnology company focused on developing best-in-class therapies that address critical unmet needs in autoimmune diseases. Jade’s lead candidate, JADE101, targets the cytokine APRIL, and is currently being evaluated in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. Jade’s pipeline also includes JADE201, an afucosylated anti-BAFF-

Funding history

Series private placement — $45.0M — Dec 2025
Funding Round — $75.8M — Aug 2020
Series seed — $2.5M — Jan 2020

Recent signals

Apr 23, 2026: Jade Biosciences Appoints Edward R. Conner, M.D. as Chief Medical Officer
Dec 15, 2025: Raised $45.0M in Series private placement
Dec 13, 2025: SEC 8-K (1.01): On December 13, 2025, Jade Biosciences, Inc. entered into a securities purchase agreement for a private placement of 3,214,286 shares of common stock at a price of $14.00 per share, generating approximately $45 million in gross proceeds. The closing of the transaction is anticipated on December 16, 2025, pending customary conditions. The funds are intended for research and development, corporate expenses, and working capital, demonstrating the company's strategic focus on expanding its operations despite current market conditions.
Jul 01, 2025: Jade Biosciences Appoints Brad Dahms as Chief Financial Officer
Aug 01, 2024: Jade Biosciences Names Andrew King as Chief Scientific Officer
Aug 14, 2020: Raised $75.8M
Jan 08, 2020: Raised $2.5M in Series seed

See plans & pricing → Track Jade Biosciences’s funding, hiring, and signals — with verified contacts — on Fundz.